Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C

Hilary Whitworth, Sarah E Sartain, Riten Kumar, Katherine Armstrong, Lance Ballester, Marisol Betensky, Clay T Cohen, Rosa Diaz, Caroline Diorio, Neil A Goldenberg, Julie Jaffray, Jacquelyn Keegan, Kendra Malone, Adrienne G Randolph, Stacey Rifkin-Zenenberg, Wendy Seto Leung, Anthony Sochet, Lakshmi Srivaths, Ayesha Zia, Leslie Raffini, Hilary Whitworth, Sarah E Sartain, Riten Kumar, Katherine Armstrong, Lance Ballester, Marisol Betensky, Clay T Cohen, Rosa Diaz, Caroline Diorio, Neil A Goldenberg, Julie Jaffray, Jacquelyn Keegan, Kendra Malone, Adrienne G Randolph, Stacey Rifkin-Zenenberg, Wendy Seto Leung, Anthony Sochet, Lakshmi Srivaths, Ayesha Zia, Leslie Raffini

Abstract

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with thrombotic complications in adults, but the incidence of COVID-19-related thrombosis in children and adolescents is unclear. Most children with acute COVID-19 have mild disease, but coagulopathy has been associated with multisystem inflammatory syndrome in children (MIS-C), a postinfectious complication. We conducted a multicenter retrospective cohort study to determine the incidence of thrombosis in children hospitalized with COVID-19 or MIS-C and evaluate associated risk factors. We classified patients into 1 of 3 groups for analysis: COVID-19, MIS-C, or asymptomatic SARS-CoV-2. Among a total of 853 admissions (COVID-19, n = 426; MIS-C, n = 138; and asymptomatic SARS-CoV-2, n = 289) in 814 patients, there were 20 patients with thrombotic events (TEs; including 1 stroke). Patients with MIS-C had the highest incidence (9 [6.5%] of 138) vs COVID-19 (9 [2.1%] of 426) or asymptomatic SARS-CoV-2 (2 [0.7%] of 289). In patients with COVID-19 or MIS-C, a majority of TEs (89%) occurred in patients age ≥12 years. Patients age ≥12 years with MIS-C had the highest rate of thrombosis at 19% (9 of 48). Notably, 71% of TEs that were not present on admission occurred despite thromboprophylaxis. Multivariable analysis identified the following as significantly associated with thrombosis: age ≥12 years, cancer, presence of a central venous catheter, and MIS-C. In patients with COVID-19 or MIS-C, hospital mortality was 2.3% (13 of 564), but it was 28% (5 of 18) in patients with TEs. Our findings may help inform pediatric thromboprophylaxis strategies.

© 2021 by The American Society of Hematology.

Figures

Graphical abstract
Graphical abstract
Figure 1.
Figure 1.
Prophylactic anticoagulation regimens in COVID-19 and MIS-C patients. (A) Proportion of admissions receiving prophylactic anticoagulation in clinical subgroups by dose intensity (n = 208 admissions). When >1 regimen was used per admission, the regimen with either the longest duration or highest dose intensity was included. For patients with TEs, only those without TEs on admission were included (n = 14). (B) Prophylactic anticoagulation regimens in patients with COVID-19 or MIS-C (n = 220 regimens; other: rivaroxaban, apixaban, bivalirudin, warfarin, or aspirin). TE, thrombotic event; UFH, unfractionated heparin.

References

    1. Zhou F, Yu T, Du R, et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062.
    1. Fogarty H, Townsend L, Ni Cheallaigh C, et al. . COVID19 coagulopathy in Caucasian patients. Br J Haematol. 2020;189(6):1044-1049.
    1. Wang D, Hu B, Hu C, et al. . Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069.
    1. Al-Samkari H, Karp Leaf RS, Dzik WH, et al. . COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489-500.
    1. Cui S, Chen S, Li X, Liu S, Wang F.. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421-1424.
    1. Helms J, Tacquard C, Severac F, et al. ; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis) . High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089-1098.
    1. Llitjos JF, Leclerc M, Chochois C, et al. . High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020;18(7):1743-1746.
    1. Middeldorp S, Coppens M, van Haaps TF, et al. . Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1995-2002.
    1. Poissy J, Goutay J, Caplan M, et al. ; Lille ICU Haemostasis COVID-19 Group . Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation. 2020;142(2):184-186.
    1. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B.. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. EClinicalMedicine. 2020; 29:100639.
    1. Lu X, Zhang L, Du H, et al. ; Chinese Pediatric Novel Coronavirus Study Team . SARS-CoV-2 infection in children. N Engl J Med. 2020; 382(17):1663-1665.
    1. Bixler D, Miller AD, Mattison CP, et al. ; Pediatric Mortality Investigation Team . SARS-CoV-2-associated deaths among persons aged <21 years - United States, February 12-July 31, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(37):1324-1329.
    1. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P.. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607-1608.
    1. Verdoni L, Mazza A, Gervasoni A, et al. . An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395(10239):1771-1778.
    1. Dufort EM, Koumans EH, Chow EJ, et al. ; New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team . Multisystem inflammatory syndrome in children in New York state. N Engl J Med. 2020;383(4): 347-358.
    1. Feldstein LR, Rose EB, Horwitz SM, et al. ; CDC COVID-19 Response Team . Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334-346.
    1. Ramcharan T, Nolan O, Lai CY, et al. . Paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK tertiary paediatric hospital. Pediatr Cardiol. 2020;41(7):1391-1401.
    1. Loi M, Branchford B, Kim J, Self C, Nuss R.. COVID-19 anticoagulation recommendations in children. Pediatr Blood Cancer. 2020;67(9): e28485.
    1. Goldenberg NA, Sochet A, Albisetti M, et al. ; Pediatric/Neonatal Hemostasis and Thrombosis Subcommittee of the ISTH SSC . Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. J Thromb Haemost. 2020;18(11):3099-3105.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG.. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2): 377-381.
    1. Harris PA, Taylor R, Minor BL, et al. ; REDCap Consortium . The REDCap Consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
    1. Cordoro KM, Reynolds SD, Wattier R, McCalmont TH.. Clustered cases of acral perniosis: clinical features, histopathology, and relationship to COVID-19. Pediatr Dermatol. 2020;37(3):419-423.
    1. Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). . Accessed 30 July 2020.
    1. Mitchell LG, Goldenberg NA, Male C, Kenet G, Monagle P, Nowak-Göttl U; Perinatal and Paediatric Haemostasis Subcommittee of the SSC of the ISTH. Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children. J Thromb Haemost. 2011;9(9):1856-1858.
    1. Abarca-Gómez L, Abdeen ZA, Hamid ZA, et al. ; NCD Risk Factor Collaboration (NCD-RisC) . Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627-2642.
    1. Ippolito Bastidas H, Márquez-Pérez T, García-Salido A, et al. . Cerebral venous sinus thrombosis in a pediatric patient with COVID-19. Neurol Clin Pract. 2020;11(2): e208-e210.
    1. Essajee F, Solomons R, Goussard P, Van Toorn R.. Child with tuberculous meningitis and COVID-19 coinfection complicated by extensive cerebral sinus venous thrombosis. BMJ Case Rep. 2020;13(9):e238597.
    1. Del Borrello G, Giraudo I, Bondone C, et al. . SARS‐CoV‐2 associated coagulopathy and thromboembolism prophylaxis in children: a single centre observational study. J Thromb Haemost. 2021;19(2):522-530.
    1. Raffini L, Huang Y-S, Witmer C, Feudtner C.. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics. 2009; 124(4):1001-1008.
    1. Miesbach W, Makris M.. COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost. 2020;26:1076029620938149.
    1. Zhang L, Feng X, Zhang D, et al. . Deep vein thrombosis in hospitalized patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: prevalence, risk factors, and outcome [published correction appears in Circulation. 2020;142(2):e33]. Circulation. 2020;142(2): 114-128.
    1. Mahajerin A, Branchford BR, Amankwah EK, et al. . Hospital-associated venous thromboembolism in pediatrics: a systematic review and meta-analysis of risk factors and risk-assessment models. Haematologica. 2015;100(8):1045-1050.
    1. Witmer CM, Takemoto CM.. Pediatric hospital acquired venous thromboembolism. Front Pediatr. 2017;5:198.
    1. Goyal MK, Simpson JN, Boyle MD, et al. . Racial and/or ethnic and socioeconomic disparities of SARS-CoV-2 infection among children. Pediatrics. 2020;146(4): e2020009951.
    1. Alcendor DJ. Racial disparities-associated COVID-19 mortality among minority populations in the US. J Clin Med. 2020; 9(8):2442.
    1. COVID-19 anticoagulation in children - thromboprophylaxis. .
    1. Diorio C, Anderson EM, McNerney KO, et al. . Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome. Pediatr Blood Cancer. 2020;67(11):e28693.
    1. Chiotos K, Bassiri H, Behrens EM, et al. . Multisystem inflammatory syndrome in children during the COVID-19 pandemic: a case series. J Pediatric Infect Dis Soc. 2020; 9(3):393-398.
    1. Diorio C, McNerney KO, Lambert M, et al. . Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv. 2020;4(23):6051-6063.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere